Qi RB, Wu ZH. Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment. World J Virol 2023; 12(1): 22-29 [PMID: 36743657 DOI: 10.5501/wjv.v12.i1.22]
Corresponding Author of This Article
Zheng-Hao Wu, MD, Doctor, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hanghang Road, Qiaokou District, Wuhan 430000, Hubei Province, China. wu_zhenghao@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Jan 25, 2023; 12(1): 22-29 Published online Jan 25, 2023. doi: 10.5501/wjv.v12.i1.22
Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment
Ruo-Bing Qi, Zheng-Hao Wu
Ruo-Bing Qi, Zheng-Hao Wu, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Ruo-Bing Qi, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Author contributions: Qi RB and Wu ZH conceived the study and wrote the manuscript.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Hao Wu, MD, Doctor, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hanghang Road, Qiaokou District, Wuhan 430000, Hubei Province, China. wu_zhenghao@126.com
Received: September 8, 2022 Peer-review started: September 8, 2022 First decision: September 19, 2022 Revised: October 3, 2022 Accepted: November 21, 2022 Article in press: November 21, 2022 Published online: January 25, 2023
Core Tip
Core Tip: In this review, we discussed the hepatotropic nature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and described the distribution of receptors for SARS-CoV-2 in the vascular endothelium and cholangiocytes of the liver. We proposed mechanisms for possible viral entry that mediate liver injury, such as liver fibrosis. Due to SARS-CoV-2-induced liver damage, many coronavirus disease 2019 (COVID-19) patients develop liver dysfunction. We discussed the longer disease duration and higher mortality following SARS-CoV-2 infection in chronic liver disease patients. Correspondingly, relevant risk factors and possible mechanisms were proposed. Finally, we discussed the potential hepatotoxicity of COVID-19-related vaccines and drugs.
